Novo Nordisk has received a Warning Letter from the US Food and Drug Administration (FDA) related to violations of postmarketing adverse drug experience (PADE) regulations. The letter relates to an inspection that took place in early 2025, in which the FDA found serious violations of PADE reporting requirements, in response to which the regulator says […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!